Figure 3.

FBXO42 is a predictive biomarker leading to trametinib resistance in NRAS‐mutant melanoma. (a) RNA sequencing performed on 23 NRAS mutant cell lines derived from melanoma patients treated with MEKi. Top bar indicates MEKi‐resistant patients in red, MEKi‐sensitive patients in blue. Scale bar indicates the expression level of the genes in the Y axis. (b) Representative immunohistochemical stain for FBXO42 in melanoma tumor slides taken from patients sensitive to MEKi treatment. Image is presented in ×10 magnification, scale 100 μm